We published the Guidelines on the Prophylactic Use of Rh D Immunoglobulin (Anti-D) in Obstetrics in 2003 to provide clinical guidance on antenatal prophylaxis. That guideline addressed supply constraints at the time of publication by including a staged implementation process for a full antenatal prophylaxis program in Australia.

In 2016, the NBA and Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) agreed on the need to update the clinical guidance on the prophylactic use of Rh D immunoglobulin while maintaining the policy intent for an antenatal prophylaxis program.

Developing the Guidelines on the Prophylactic Use of Rh D Immunoglobulin (Anti-D) in Obstetrics was a joint project between RANZCOG and the NBA. Representatives from RANZCOG were joined by other experts from various clinical settings on the Expert Reference Group to develop the guideline. The NBA gratefully acknowledges the dedication and expertise provided by the Expert Reference Group.

The guideline was published on 28 May 2021.

It introduces new clinical guidance on the use of non-invasive prenatal testing (NIPT) to determine fetal Rh D status. This guidance is based on scientific evidence and consensus among clinical experts and is not a policy statement on funding and supply arrangements for the national provisions of NIPT. The existing supply arrangements and status of the application for new MBS items for the national provision of NIPT to determine fetal RHD status are not addressed specifically in this guideline.

Technical report on the methodology and findings of the evidence review process

Complementary educational resources

The 'RhD Immunoglobulin' obstetric patient blood management course is available from BloodSafe eLearning(Opens in a new tab/window).

Last updated: 27 Mar 2024